Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
- Dodel, Richard
- Rominger, Axel
- Bartenstein, Peter
- Barkhof, Frederik
- Blennow, Kaj
- Förster, Stefan
- Winter, Yaroslav
- Bach, Jan-Philipp
- Popp, Julius
- Alferink, Judith
- Wiltfang, Jens
- Buerger, Katharina
- Otto, Markus
- Antuono, Piero
- Jacoby, Michael
- Richter, Ralph
- Stevens, James
- Melamed, Isaac
- Goldstein, Jerome
- Haag, Stefan
- Wietek, Stefan
- Farlow, Martin
- Jessen, Frank
DOIAbstract
Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients
Add to ORKG